Dual targeting of mir-208 and mir-499 in the treatment of cardiac disorders
AssigneeBoard of Regents, The University of Texas System
InventorsEric N. OLSON, Eva van Rooij
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of treating or preventing cardiac disorders in a subject in need thereof by inhibiting the expression or function of both miR-499 and miR-208 in the heart cells of the subject. In particular, specific protocols for administering inhibitors of the two miRNAs that achieve efficient, long-term suppression are disclosed. In addition, the invention provides a method for treating or preventing musculoskeletal disorders in a subject in need thereof by increasing the expression or activity of both miR-208 and miR-499 in skeletal muscle cells of the subject.
Claims24
1-25. (canceled)
A method for treating pathologic cardiac hypertrophy, myocardial infarction, or heart failure in a subject in need thereof comprising administering to the subject a nucleic acid molecule comprising a first miRNA targeting sequence and a second miRNA targeting sequence, wherein the first miRNA targeting sequence is at least partially complementary to a mature miR-208a or miR-208b sequence and the second miRNA targeting sequence is at least partially complementary to a mature miR-499 sequence, and wherein the expression or activity of miR-208a or miR-208b and miR-499 is reduced in the heart cells of the subject following administration of the nucleic acid.
Dependencies are inferred from the claim text.